Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) is suspected to confer an increased risk for developing type 2 diabetes (DM). However, only a few prospective studies evaluated NAFLD as a predictor for DM, most did not adjust for the full range of potential cofounders and none used an objectively quantified degree of steatosis. Our aim was to evaluate the independent role of NAFLD in predicting the development of pre‐DM in a 7‐year prospective follow‐up of healthy volunteers. Methods: A prospective cohort of a subsample of the Israeli National Health Survey evaluated at baseline and after 7 years by identical protocols. Metabolic parameters and ultrasonographic evidence of NAFLD were evaluated in 213 subjects, without known liver disease or history of alcohol abuse. Exclusion criteria were pre‐DM at the baseline survey. Steatosis was quantified by ultrasound with the hepato‐renal ultrasound index (HRI). Results: The study included 141 volunteers (mean age 48.78 ± 9.68, 24.82% with NAFLD) without pre‐DM/DM at baseline. Both NAFLD on regular US (OR=2.93, 1.02–8.41 95%CI) and HRI (OR=7.87, 1.83–33.82) were independent predictors for the development of pre‐DM, adjusting for age, gender, BMI, family history of DM, baseline insulin, adiponectin and glucose. Further adjustment for physical activity and dietary intake did not weaken the association. Furthermore, NAFLD was a stronger predictor for pre‐DM than the metabolic syndrome. Subjects with both NAFLD and glucose ≥89 had 93.3% incidence rate of pre‐DM. Conclusion: Non‐alcoholic fatty liver disease is a strong and independent risk factor for pre‐DM in the general adult population; thus, NAFLD patients should be classified as a population at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., Paciorek, C. J., Lin, J. K., Farzadfar, F., Khang, Y.-H., Stevens, G. A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60679-x · Cited by 3,568
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000380842.14048.7e · Cited by 1,600
Vozarova, B., Stefan, N., Lindsay, R. S., Saremi, A., Pratley, R. E., Bogardus, C., & Tataranni, P. A. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1889 · Cited by 717 · cited 1×
“As steatosis leads to decreased hepatic insulin sensitivity and increased gluconeogenesis (7, 8), it is hypothesized that NAFLD precedes the development of DM.”
BackgroundDevelopment of Muscle Insulin Resistance After Liver Insulin Resistance in High-Fat–Fed Rats
Kraegen, E. W., Clark, P. W., Jenkins, A. B., Daley, E. A., Chisholm, D. J., & Storlien, L. H. (1991) · Diabetes · doi:10.2337/diab.40.11.1397 · Cited by 601 · cited 1×
“In a similar experiment in rats, fat feeding induced insulin resistance in liver before skeletal muscle, leading to increased gluconeogenesis and an oversupply of energy substrate to skeletal muscle that may have generated later muscle insulin resistance (47).”
BackgroundCellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
Cited by
Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., Roverato, A., Guaraldi, G., & Lonardo, A. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13264 · Cited by 717
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
Alexander, M., Loomis, A. K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1103-x · Cited by 272
Salomone, F., Godos, J., & Zelber‐Sagi, S. (2016) · Liver International · doi:10.1111/liv.12975 · Cited by 260
Self-citation
Metadata
- Authors
- Zelber‐Sagi, S., Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan‐Kaluski, D., Halpern, Z., Santo, E., & Oren, R.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2013-05-08
- Volume
- 33
- Issue
- 9
- Pages
- 1406-1412
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2128634817
- Cited by
- 88
- References
- 14
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up. https://app.cochat.ai/papers/10.1111/liv.12200
- The paper
- Zelber‐Sagi, S., Lotan, R., Shibolet, O., Webb, M., Buch, A., Nitzan‐Kaluski, D., Halpern, Z., Santo, E., & Oren, R. (2013). Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐up. Liver International. https://doi.org/10.1111/liv.12200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.